Item 2.02 Results of Operations and Financial Condition.
On January 5, 2022, Albireo Pharma, Inc. ("Albireo") issued a press release (the
"Press Release") reporting the preliminary unaudited amount of net sales for the
year ended December 31, 2021 of Albireo's product Bylvay and the preliminary
unaudited amount of Albireo's cash and cash equivalents for the year ended
December 31, 2021. These amounts are preliminary, unaudited and may change, were
prepared by management and are based on the most current information available
to management, and are subject to completion by management of the financial
statements as of and for the year ended December 31, 2021, including completion
of the review procedures, final adjustments and other developments that may
arise between now and the time the financial results for this period are
finalized, and completion of the audit of such financial statements.
Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January 3, 2022, Roger A. Jeffs, Ph.D, a member of the board of directors of
Albireo, resigned effective as of January 3, 2022 to pursue other opportunities.
Dr. Jeffs' departure was not the result of any disagreement regarding any matter
relating to Albireo's operations, policies or practices.
Item 7.01 Regulation FD Disclosure.
The Press Release issued on January 5, 2022 also provides an update on Albireo's
BOLD Phase 3 study in biliary atresia and Albireo's ASSERT Phase 3 study in
Alagille syndrome and announces the departure of Dr. Jeffs from Albireo. A copy
of the press release is furnished as Exhibit 99.1 to this Current Report on
Form 8-K.
The information in Current Report on Form 8-K (including Exhibit 99.1) is being
furnished and shall not be deemed to be "filed" for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or
otherwise subject to the liabilities of that Section, nor shall it be deemed
incorporated by reference into any registration statement or other filing under
the Securities Act of 1933, as amended, or the Exchange Act, except as shall be
expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. Description
99.1 Press Release issued by Albireo Pharma, Inc. on January 5, 2022
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
© Edgar Online, source Glimpses